A B S T R A C T For plethysmographic studies of lung mechanics and measurement of pulmonary diffusing capacity, 62 subjects were drawn from a randomly selected population sample. Data obtained from the 24 subjects of heterozygous phenotype for alpha-l-antitrypsin deficiency (PiMZ) were compared by age group with data from 38 normal (PiM) subjects matched for sex, age, and smoking history. Comparison of mean values by age group for lung volumes, diffusing capacity, lung elastic recoil, maximum expiratory flow, and the occurrence of frequency dependence of dynamic compliance revealed no differences between phenotype groups. There was no evidence of an accelerated effect of aging among PiMZ subjects when compared with normal counterparts nor was there evidence of an increased effect of smoking. From these data it appears that the PiMZ phenotype per se is not a risk factor in the development of emphysema.
INTRODUCTION
The etiology of emphysema is still unknown, though many factors, genetic and environmental, acting singly or in concert, have been implicated. The suggestion by Laurell and Eriksson (1) in 1963, soon confirmed by Eriksson (2, 3) , that a genetically determined deficiency Dr. McDonagh was a Fellow of the American Lung Association. Dr. Nathan was a Fellow supported by National Research Service Award HL07243.
Received for publication 5 September 1978 and in revised form 23 October 1978. of alpha-l-antitrypsin was associated with clinical emphysema provided the first identification of a longsought hereditary factor. Subsequent reports have substantiated the increased risk of individuals homozygous for, and with a severe degree of, alpha-l-antitrypsin deficiency (PiZ)' (4) (5) (6) (7) (8) . Although the absolute risk of PiZ individuals for developing emphysema is uncertain, Black and Kueppers (9) recently suggested that the clinical course may be quite variable, and that, in the absence of respiratory irritants, the prognosis may not be as ominous as previously indicated.
Even if the PiZ phenotype constitutes an inherited risk factor, it occurs in only a small proportion (0.1-0.3%) of the population and can account for a proportionately small proportion of the total number of cases of pulmonary emphysema. A larger proportion of the general population (=3%) is of the protease inhibitor phenotype heterozygous for alpha-l-antitrypsin de-ficiency (PiMZ) . The relative risk of emphysema occurring in PiMZ individuals has also been studied, but the results have been quite conflicting. Early studies addressing this question were limited by the serum trypsin inhibitory capacity as the only available measurement to identify heterozygous individuals. Because alpha-l-antitrypsin is an acute phase reactant, the serum level can vary widely depending on such factors as the presence of inflammation or the influence of estrogens, and this can result in PiMZ individuals being mistaken for normal (PiM) individuals (10) . The recent use of starch-gel electrophoresis followed by crossed immunoelectrophoresis (11) and electrofocusing (12) have allowed for exact phenotyping, and have thus circumvented the problem of inadequate identification.
Some ofthe conflicting data in the PiMZ studies have resulted from the use of physiologic tests too insensitive to detect early or subtle pathophysiologic changes. Indeed, Gelb et al. (13) , in a study correlating the anatomic and physiologic findings in subclinical emphysema, emphasized the insensitivity of lung volume measurements, vital capacity, timed vital capacity, and airway resistance in unveiling the diagnosis. These authors concluded that, short of the direct measurement of lung elastic recoil, the maximum expiratory flow-volume curve and the measurement ofthe diffusing capacity were the most sensitive parameters to be obtained.
Another factor adding to the confusion about the relative risk of PiMZ phenotypes and emphysema has been the populations under study. In those studies involving patients with chronic obstructive pulmonary disease (COPD) (14) (15) (16) , the relatives of such patients or other obligate heterozygotes (17) (18) (19) , and nonrandomly selected PiMZ individuals (20) , the results have generally suggested that PiMZ individuals are at significant risk for developing emphysema. In contrast, those reports involving random populations (21) (22) (23) (24) (25) (26) , epidemiologic health surveys (27) , and individuals within an age strata of a general population (28) have generally demonstrated either no risk or a minimal risk for emphysema.
To address the question of the risk of PiMZ phenotypes for premature emphysema, we undertook the study of subjects with accurately defined protease inhibitor phenotypes from a randomly selected population utilizing detailed physiologic testing. The remainder of this paper constitutes the results of our endeavor.
METHODS
A random, stratified, cluster sample ofthe white, non-Mexican Americans ofTucson, Ariz. had been identified as the population for a prospective longitudinal study ofthe natural history of chronic obstructive lung disease (29) . Of this population, 92.4% of subjects over the age of 5 yr had blood samples drawn for alpha-l-antitrypsin screening. Satisfactory protease inhibitor (Pi) phenotype was determined on 2,944 subjects (21) together with serum trypsin inhibitory capacity (STIC) (23) . The STIC was determined by a modification of the method of Laurell and Eriksson (1) , and the Pi phenotypes were determined by discontinuous acid starch-gel electrophoresis followed by crossed immunoelectrophoresis (11) . Mean STIC for the total population was 1.45 mg/ml. 3% of those tested, or 88 subjects, were PiMZ phenotype. The mean STIC ofthese PiMZ subjects was 68±15.3% ofthe mean for the total population.
Because physiological changes that occur during growth and development introduce additional variables and depend on the rate of maturation, for this study we excluded subjects under 25 yr of age. There were 47 adult PiMZ subjects above this age considered eligible for study. To obtain an adequate number ofcontrol subjects, 80 people were identified from the 2,637 persons of PiM phenotype, matched with the PiMZ subjects for sex, age, and smoking history.
Not all the potential candidates thus identified participated in full. Of the 47 PiMZ subjects, 1 had died, and 2 had moved out of the city since first enrolled. 5 refused all testing, and 10 were excluded because of confounding variables of severe cardiovascular disease, malignancy, mental retardation, physical disability precluding body plethysmography, or advanced age (over 75 yr). Because of technical difficulties or poor subject compliance, only partial data were obtained on five subjects. Complete studies were performed on 24, or 51%, of the original 47 PiMZ subjects. Of the 80 matched PiM control subjects identified, 1 had died, 4 relocated, 13 refused, and 7 were excluded because of confounding variables and advanced age. Partial data were obtained on 17 subjects because ofpoor compliance, technical difficulties, and, in two subjects, because of pulmonary impairnent. Thus, complete studies were performed on 38, or 48%, of the original 80 PiM subjects. For purposes of data analysis, subjects were divided into three age groups. The characteristics of these groups are listed in Table I . The mean STIC was 1.45 mg/ml (±0.34) for the 38 PiM subjects and 1.09 mg/ml (±+0.31) for the 24 PiMZ subjects who participated in this study.
All subjects signed informed consent, and all were given detailed instructions before each of the physiologic tests. It was required that each subject had been free ofany symptoms ofan upper respiratory tract infection for at least 4 wk before testing.
Initial tests consisted ofat least three satisfactory forced vital capacity maneuvers. Data were recorded as flow through a pneumotachograph field device (30) , digitized, and analyzed using computer techniques previously described (31) . The best forced vital capacity (FVC) and the best forced expiratory volume in the first second (FEV1) were selected and the FEV,/FVC ratio derived. Lung diffusing capacity for carbon monoxide was measured in duplicate with a Collins Modular Lung Analyzer (Warren E. Collins, Inc., Braintree, Mass.) the single-breath method of Ogilvie et al. (32) , and the best of the measurements was recorded as diffusing capacity per unit lung volume.
The remainder of the physiologic studies were performed with subjects seated in a pressure-compensated, integratedflow, volume displacement body plethysmograph (J. H. Emerson Co., Cambridge, Mass.). Air conditioning was controlled for thermal stability and a final volume calibration adjustment was made. Flow at the mouth was measured by a Fleisch pneumotachograph connected to a differential pressure transducer (Sanbom 270). The dead space of the apparatus was reduced to that of the mouthpiece alone by a bias flow from the environment through the pneumotachograph toward the mouth at a flow of 0.5 liters/s. The bias flow (33) . A 10-cm balloon (0.06-mm thickness, 3.5-cm perimeter) mounted on a 110-cm long polyethylene tube (PE 200), was passed transnasally into the esophagus to the point of the maximum negative pressure with the least cardiac artifact. For each balloon used, the optimum volume had been previously determined by the water immersion technique ofLemen and co-workers (34) , and this volume was checked periodically throughout the study.
Thoracic gas volume at functional residual capacity (FRC) was determined by the method of DuBois et al. (35) , after which the subject inspired maximally to total lung capacity (TLC) and then expired maximally to residual volume (RV). Maximal expiratory flow-volume (MEFV) curves were measured as mouth flow vs. plethysmographic volume and were recorded on a cathode ray storage oscilloscope (Tektronix 564B, Tektronix, Inc., Beaverton, Oreg.) from which they were transcribed onto graph paper by use of a beam splitter. The best of three endeavors or two reproducible curves constituted the MEFV envelope. Maximum flow (Vm,) was then tabulated at increments of the vital capacity and TLC.
After a volume history of three maximal inspirations from FRC, a static deflation pressure-volume curve (P-V) was obtained. The final P-V curve was the best fit by eye to the values derived from at least three static deflation maneuvers, and the static compliance was calculated as the 0.5-liter vol change above FRC on this curve divided by the corresponding pressure change. The subjects then breathed in time to a metronome at rates of 20, 40, 60, 80 , and 100 breaths/min, and dynamic compliance (Cdyn) was calculated at these frequences. Results were corrected mathematically for inertance (36) , and expressed as the ratio of the lowest Cdyn value divided by the Cdyn value at the lowest respiratory frequency.
Resistance upstream from the equal pressure point (37) 
RESULTS
The anthropometric data, smoking status, lung volumes, static recoil pressures, maximum expiratory flows, and lung diffusion are listed by Pi phenotype for each subject by age group in Table II. Table III lists the means, SE, and SD for these same physiologic parameters by Pi phenotype, with the subjects categorized into young (25-41 yr), middle-aged (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) yr), and elderly (60+ yr) age groups. The Pst(L) and Vmax data are given at percent increments of the TLC only to 40% of TLC because measurement of Pst(L) is considered to be unreliable at lower lung volumes using the esophageal balloon technique (33) .
The static lung volumes and vital capacity changed as anticipated with increasing age, but these trends were not significant. The RV/TLC ratio increased significantly and by the same order of magnitude in both groups, a finding consistent with previous reports (38) . When the PiM and PiMZ subjects were compared by age groups, no significant difference was found in any lung volume or in RV/TLC ratios.
The flow data were size-compensated by dividing these values by the TLC, and the mean flows were then plotted at percent increments of the expired vital capacity (VC) for each age group within a phenotype. The resulting MEFV curves are shown in Fig. 1 . Maximum lung deflation or RV is represented by 100% expired VC on the abscissa. With advancing age, both the PiM and PiMZ subjects showed a decrease in Vmax that was statistically significant only after 70% of the VC had been expired. This age-related decrease in terminal flows is consistent with the data of Knudson et al. (39) , although the study populations are not similar. Although the age-related decrease in flows appears greatest in the middle-aged PiMZ subjects, this was not statistically significant. Analysis of variance in all age groups revealed no significant difference between PiM and PiMZ subjects in any measured flows.
The static deflation P-V curves for each age group within a phenotype are depicted in Fig. 2 . The mean Pst(L) values in centimeters H20 for each age group are plotted at increments of the TLC to standardize for lung size. Within each phenotype, there was a loss of lung elastic recoil with increasing age, with the greatest loss occurring at high lung volumes. When the PiM and Alpha-l-Antitrypsin Deficiency Heterozygosity PiMZ subjects were compared by age groups, no sta-calculated as the slope of the P-V curve over the 0.5-tistical difference was found, and the curves were liter vol above FRC, were not statistically significant in similar enough to be superimposable. Similar differ-any of the age groups. ences between phenotype groups in static compliance, To assess the rate of loss of lung elastic recoil, age regressions were developed from the P-V data for all subjects collectively, and separately for each phenotypic group. In Table IV , these age regressions are shown for the Pst(L) at decile increments from 100 to 50% of the TLC. For comparison, the data of Knudson and associates (39) have been included, although the latter were obtained from a highly select group of normal subjects ofthe PiM phenotype. A plot ofthe rate of loss of recoil per year of age is shown in Fig. 3 . From this figure it is apparent that our subjects, viewed either collectively or by phenotype, lose elastic recoil at a greater rate than those subjects studied by Knudson Pst(L) (cm H20) 40 FIGURE 2 Mean static deflation P-V curves by age group for PiM subjects (top) and PiMZ subjects (bottom). Volume is expressed as percent of TLC to compensate for differences in size.
Alpha-l-Antitrypsin Deficiency Heterozygosity To examine the contribution of smoking as an additive factor disposing PiMZ subjects to premature emphysema as has been reported (8, 17, 20) , we separated the subjects in both phenotypes into smokers and nonsmokers. Smokers included those who were currently or had previously smoked cigarettes on a regular basis, and nonsmokers included those who had never smoked or those who had smoked cigarettes only occasionally. As shown in Table II , approximately twothirds of the subjects would be considered smokers. When analyzed as described, no significant difference was found between PiM and PiMZ smokers in lung volumes, size-compensated flows, P-V data, upstream resistance, or diffusing capacity. Because the limited k.. Table IV. number of smokers prohibited extensive analysis of the dose effect of smoking, subtle changes were sought by studying age regressions in only those PiM and PiMZ subjects who smoked more than one pack of cigarettes per day. This included 16 PiM and 13 PiMZ subjects. Age regressions were developed to examine both the loss of size-compensated flow and lung elastic recoil, and both of these regressions failed to demonstrate an accelerated loss in either parameter in the PiMZ smokers with increasing age.
DISCUSSION
It is clear that only a fraction of those people exposed to the same environmental or microenvironmental factors, such as cigarette smoke, develop clinical emphysema. It is tempting to postulate that other factors must also be present to render certain individuals susceptible to developing the disease and that such factors may be constitutional or hereditary. Although both Osler (40) and Flint (41) suggested that emphysema may be a hereditary affliction, this has long been a matter of some controversy. In 1831-1833, James Jackson, Jr., (1810-1834), while working with P-C-A. Louis (42) , a pioneer in the collection, enumeration, and critical analysis of medical observations, first called attention to a familial predisposition to develop emphysema. Very soon, in 1845, the concept of emphysema as a hereditary disease was brought into question by Watson (43) with the words "I am not convinced ." As data continue to accumulate, it indeed appears that heredity does play a role but the specific genetic factors contributing to the development of emphysema remain largely unknown. McKusick et al. (44) speculated that these genetic factors are of a complex nature, with many genes operating under the influence of the environmental stresses to which an individual is subjected. In an attempt to control for the effect of environmental stresses, Larson et al. (45) those of their spouses. Although the first degree relatives had seven times more abnormalities in these tests than their spouses cohabitating the same environment, alpha-l-antitrypsin could be associated with only a few abnormal studies. The authors concluded that other genetic factors must exist to account for the observed abnormalities of pulmonary function. Cohen and associates (46) also observed a familial aggregation of pulmonary impairment which exists independent of phenotype or smoking history. The association of a genetically determined deficiency of alpha-l-antitrypsin and clinical emphysema provided the first concrete scientific evidence for a hereditary factor involved in the etiology of emphysema. A homozygous deficiency of alpha-l-antitrypsin has frequently been associated with the development of premature clinical emphysema, but the relationship of a heterozygous deficiency, with intermediate serum levels of alpha-l-antitrypsin, and emphysema has remained a controversial issue.
The pivotal point of the heterozygote controversy is whether or not individuals with the PiMZ phenotype are at increased risk for premature clinical emphysema. An abundance ofevidence exists supporting either contention. The differing populations from which the alpha-l-antitrypsin-deficient subjects were selected, the laboratory techniques used to identify these subjects, and the design of the individual studies, make it extremely difficult, if not impossible, to reconcile the opposing conclusions. Those studies in which the PiMZ subjects were drawn from a large, general population have tended to conclude that PiMZ subjects are not predisposed to premature clinical emphysema (21, (23) (24) (25) (26) (27) . Conversely, a great many of the studies involving PiMZ subjects drawn from highly select populations of COPD patients and their relatives have concluded that the PiMZ phenotype does predispose individuals to premature clinical emphysema (14) (15) (16) 20) . It is possible, however, that the reports of an increased incidence of premature emphysema in highly select populations are a consequence of the inclusion of other genetic factors in the population selection process. These other genetic factors may operate as modifying genes (47) with the PiMZ phenotype in the development of premature emphysema.
In a study of nonsmokers, Hall and co-workers (48), drawing from subjects attending a disease detection unit, found that 15 PiMZ subjects had significantly lower maximum expiratory flows than a comparable group of PiM subjects. These results differ from those reported from our randomly selected general population (21, 22) .
Although our data did not demonstrate a difference between our PiMZ and PiM smokers, other studies have found PiMZ smokers to be at greater risk for emphysema (8, 17, 20, 26 (25) . Further investigation of these and other environmental factors, and their influence on the Pi phenotypes is currently under investigation (46) .
The available data on the lung elastic recoil, the accepted hallmark of emphysema, of PiMZ subjects also differs depending upon the nature of the population from which the PiMZ subjects were selected. Ostrow Lung elastic recoil decreases with increasing age, and this loss of recoil may be accelerated in alpha-lantitrypsin heterozygotes. Many physiologic tests such as spirometric or flow-volume measurements and the single-breath nitrogen test, may be too insensitive to detect subtle changes in lung elastic recoil. Therefore, we studied the mechanical properties of the lung in PiMZ subjects and compared these results with a group of PiM subjects matched by age, sex, and smoking history. All subjects were selected from the same random population sample.
Our data, derived from measurements of lung volumes, maximum expiratory flows, static deflation P-V curves, upstream segment resistance, Cdyn, and lung diffusing capacity, show no differences between the PiMZ and PiM subjects when compared by age groups for any of the parameters studied. Lung elastic recoil decreased with advancing age in all subjects in this cross-sectional study, but comparison ofthe PiMZ subjects with the PiM subjects revealed no evidence of an accelerated loss of lung elastic recoil in the PiMZ subjects. We also compared our PiMZ data with the data on the aging of the normal lung reported by Knudson et al. (39) . To isolate the effects ofaging, Knudson et To assess the magnitude of this loss, the mean P-V curves for the PiMZ age groups were compared with the range ofnormal mean P-V data described by Knudson and co-workers, and this is shown in Fig. 4 . It is apparent that the P-V data of our PiMZ subjects lie within the range of normal derived from the P-V data of this highly select group of normal subjects. The greater loss of lung elastic recoil seen in the age regressions ofour subjects compared with these normal subjects can be accounted for by the fact that the same rigorous selection criteria regarding smoking, roentgenographic and vectorcardiogram abnormalities, FEV1/FVC ratios, and cardiopulmonary signs and symptoms were not applied to our subjects.
Our data, utilizing detailed physiologic measurements, are an extension of the results previously reported from studies of the same general population from which our PiMZ and PiM subjects were selected. Morse et al. (21) determined the Pi variants in the population and found no significant differences in the prevalence ofrespiratory symptoms and the prevalence ofphysician-confirmed respiratory disease between the PiMZ and PiM subjects. In addition, no significant differences were found in the FEV,, FVC, FEV,/FVC ratio, and Vmax at 25, 50, and 75% of the expired VC between the Pi phenotypes. Lebowitz FIGURE 4 Mean static deflation P-V curves by age group for PiMZ subjects. The stippled area depicts the range of the mean curves from Knudson and co-workers (39) using as limits the mean curve for their young men and their elderly women. The mean curves for PiMZ subjects fall within these limits. age groups and by smoking status. On the basis ofthese cumulative observations, we conclude that PiMZ subjects do not differ symptomatically or physiologically from PiM subjects in a randomly selected population. The data suggest that the PiMZ phenotype per se does not predispose individuals to premature clinical emphysema and the data provide no evidence that PiMZ smokers are at greater risk for developing emphysema than PiM smokers.
